Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Part of paid clinical trials in Duarte, California.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT04858256
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lymphoproliferative Disorders
  • T-Cell Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Pacritinib will be dosed at 200mg twice daily.

Study Details

The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.

Key Dates

Start date
Mar 29, 2023
Status verified
Jan 2026
Primary completion
Nov 30, 2027
Completion
Nov 30, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: PTCL, NOS
    Patients will receive single agent pacritinib.
  • Experimental: Cohort 2: AITL/TFH PTCL
    Patients will receive single agent pacritinib.
  • Experimental: Cohort 3: CTCL (MF/SS)
    Patients will receive single agent pacritinib.
  • Experimental: Cohort 4: Less common PTCL subtypes
    Patients will receive single agent pacritinib.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: Up to 2 years ]

Locations (6)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Christina Poh
[email protected]
626-713-7102
Christina Poh, MD (PRINCIPAL_INVESTIGATOR)
Moffitt Cancer CenterTampaFlorida33612
Lubomir Sokol
[email protected]
813-745-6100
Lubomir Sokol (PRINCIPAL_INVESTIGATOR)
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109
Cancer AnswerLine
[email protected]
800-865-1125
Ryan Wilcox, MD, PhD (PRINCIPAL_INVESTIGATOR)
Duke Cancer InstituteDurhamNorth Carolina27710
Jie Wang
[email protected]
919-668-1000
Jie Wang (PRINCIPAL_INVESTIGATOR)
Ohio State University Comprehensive Cancer CenterColumbusOhio43202
John Reneau
[email protected]
614-685-2330
John Reneau (PRINCIPAL_INVESTIGATOR)
University of Pittsburgh Medical CenterPittsburghPennsylvania15232
Natalie Galanina
[email protected]
412-684-7764
Natalie Galanina (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By research site
City of Hope· Duarte, CAMoffitt Cancer Center· Tampa, FLUniversity of Michigan Rogel Cancer Center· Ann Arbor, MIDuke Cancer Institute· Durham, NCOhio State University Comprehensive Cancer Center· Columbus, OHUniversity of Pittsburgh Medical Center· Pittsburgh, PA

Related Studies